Opening up the web to the blind

Article

WebAnywhere, a new web tool that allows the blind to surf the web "on the go", without any additional software or installation requirements, has been launched.

WebAnywhere, a new web tool that allows the blind to surf the web “on the go”, without any additional software or installation requirements, has been launched.

The web-hosted tool, which reads aloud text on web pages and requires only that the computer has speakers, will open up the opportunities of the mobile internet to the blind, who previously were reliant on specially-installed screen-reading software, typically installed only on their own computers. In tests, users were able to use the internet to check email, look up a bus schedule and find a restaurant phone number on a variety of different computers and connections.

WebAnywhere was developed by Jeffrey Bigham, a doctoral student, under the supervision of Richard E. Ladner, BS, PhD at the University of Washington, US and with the support of the National Science Foundation. The access technology program, currently only available in English, is available free of charge.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.